| Ticker: | CMMB |
| Current Price: | $1.53 |
| % Daily Change: | 9.29% |
| Volume (1,000s): | 85.49 |
| Average Volume (1,000s): | 128.90 |
| Market Cap (M): | $10.14 |
| 1/2/2024 Price: | $0.54 |
| Change Since Inception: | 184.49% |
Chemomab Therapeutics Ltd.
Building 7
Kiryat Atidim
Tel Aviv, 6158002
Israel
Chemomab is a clinical stage biotechnology company discovering and developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the chemokine CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to neutralize CCL24 activity. In preclinical and clinical studies to date, CM-101 appears safe and well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. The company has reported encouraging results from a Phase 2 biomarker study in NASH patients and an investigator study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis patients is ongoing.